Smith, Matthew R.

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 930

Changes in body composition during androgen deprivation therapy for prostate cancer

Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism

Prostate Cancer Treatment and ResearchNutrition and Health in Aging

Cited by 697

Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer

Potosky, A. L., Haque, R., Cassidy-Bushrow, A. E., Ulcickas Yood, M., Jiang, M., Tsai, H.-T., Luta, G., Keating, N. L., Smith, M. R., & Van Den Eeden, S. K. (2014) · Journal of Clinical Oncology

Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and Research

Cited by 75

Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer

Michaelson, M. D., Marujo, R. M., & Smith, M. R. (2004) · Clinical Cancer Research

Bone health and treatmentsProstate Cancer Treatment and Research

Cited by 60

Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results

Tombal, B., Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., Iversen, P., Braeckman, J., Heracek, J., Baron, B., et al. (2018) · Journal of Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 26